CELLINK has been granted its first patent of robotic systems for personalized and automated aesthetic medical procedures
CELLINK has been granted a patent for a unique set of robotic systems for transcutaneous delivery of substances, such as cosmetic or surgical fillers, into patients. This is CELLINK’s first granted patent in the field of personalized and automated aesthetic medical procedures - combining the strengths of 3D bioprinting, biomaterials, robotics, automation, and artificial intelligence to optimally administer substances, such as dermal fillers, into subcutaneous regions to improve aesthetical outcomes in patients. This is one technological example of the power of Bioconvergence. This patent protection applies to the Swedish market. The company is also expanding patent protection in the USA and other important markets.
The patent protection (SE 543714) from the Swedish Patent and Registration Office shows novelty, inventive step, and industrial applicability. Aesthetic plastic surgery is a field where CELLINK sees great opportunities and potential to disrupt by personalizing, digitizing, and automating the processes. The patented invention covers the use of a person’s 3D face scan as a digital input to compare to the person’s desired bodily features. Based on the results from the artificial intelligence powered algorithm, determine an optimal substance dispensing plan that can be executed autonomously and precisely by a robotic arm in the required facial regions with the adequate type of dermal filler and amounts. The personalized and automated approach may provide a faster and more accurate substance dispensing plan than a human counterpart would be able to do, may reduce treatment times and probability of complications associated with dispensing the substance, while simultaneously achieving superior results compared to the human counterpart.
“This invention shows our innovative research & development capabilities and passion to improving patient’s outcomes, whether for cosmetic or reconstructive surgery. This granted patent can potentially offer commercial opportunities for the CELLINK Group. We foresee that this robotic system enables cutting-edge possibilities to deliver personalized aesthetic outcomes and we will continue to explore it”, says Dr. Héctor Martínez, CTO CELLINK.
The granted patent strengthens the company's protection for intellectual properties and complements a full portfolio of solutions being developed at CELLINK.
For further information, please contact:
|Erik Gatenholm, CEO
Phone (Sweden): +46 73 267 00 00
Phone (US): +1 (650) 515 5566
|Gusten Danielsson, CFO
Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (857) 332 2138
This is information that CELLINK AB (publ) submitted for publication, through the agency of the contact persons set out above, on June 30, 2021 at 08:45 (CEST).
Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products, and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,700 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq the Stockholm under CLNK B. www.cellink.com